Skip Navigation

Annals of Oncology 2006 17(3):355; doi:10.1093/annonc/mdl040
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

in this issue

in this issue

The first 10% of the full text of this article appears below.


   Survival in BRCA1-associated breast cancer
 
Studies comparing survival in BRCA1-associated and sporadic breast cancer report inconsistent results and frequently concern small sample sizes. Moreover, the impact on survival of the classical prognostic factors, e.g. tumor size and nodal status, has not been investigated separately in BRCA1-associated tumors. However, there are indications that this impact might differ from that seen with sporadic cases. In this issue, Brekelmans et al. report a . . . [Full Text of this Article]


   5-FU/leucovorin and 3H1 in colorectal cancer
 

   Chlamydia eradication in orbital lymphoma
 

   Three-weekly vs. weekly docetaxel in advanced NSCLC
 

   Quote
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?